Pharmaceutical Analysis, pharmaceutical product development.#Pharmaceutical #product #development

Posted On Sep 6 2018 by

Pharmaceutical Analysis Specialist pharmaceutical analysis services to support development programs (R ?>


PHARMACEUTICAL BRAND NAMING, BRAND INSTITUTE, PRODUCT NAME DEVELOPMENT SERVICES, GLOBAL BRANDING, BRANDING CONSULTANTS LOS ANGELES, NEW YORK, TORONTO, TOKYO, pharmaceutical product development.#Pharmaceutical #product #development

Posted On Sep 6 2018 by

Welcome to Brand Institute. We name more products than anyone in the world! Recent Healthcare Approvals Brand ing Brand Institute is the world’s premier brand identity consultancy. Our brand agency portfolio of services includes brand strategy/architecture, name development, market research, regulatory and visual identity solutions.


Pharmaceutical Particle Size, Shape, Surface Area and Stability, pharmaceutical product.#Pharmaceutical #product

Posted On Apr 23 2018 by

pharmaceutical product in the Pharmaceutical Industry The particle size distribution of active ingredients and excipients is an important physical characteristic of the materials used to create pharmaceutical products. The size, distribution and shape of the particles can affect bulk properties, product performance, processability, stability and appearance of the end product. The link between particle size and product performance is well documented with regards to dissolution, absorption rates and content uniformity. Reducing particle size can aid the formulation of NCE’s with poor water solubility. Proper matching of active ingredient and excipient particle size is important for several process steps. Particle size …


Pharmaceutical Technology, pharmaceutical product development.#Pharmaceutical #product #development

Posted On Mar 13 2018 by

pharmaceutical product development Pharmaceutical Technology is using cookies We use them to give you the best experience. If you continue using our website, we’ll assume that you are happy to receive all cookies on this website. Log In Clinical Trials LIFNano: can nanotech ‘flip the switch’ to cure multiple sclerosis? Red sage: could this ancient Chinese herb prevent bone loss? Nutraceuticals are being held back by regulatory confusion Cold Chain Evocalcet faces stiff competition in Japan’s CKD-induced hyperparathyroidism market Blockchain in pharma: opportunities in the supply chain Are drug expiration dates fit for purpose? Diseases LIFNano: can nanotech ‘flip the …


Pharmaceutical Analysis, pharmaceutical product development.#Pharmaceutical #product #development

Posted On Mar 13 2018 by

Pharmaceutical Analysis Specialist pharmaceutical analysis services to support development programs (R ?>


PHARMACEUTICAL BRAND NAMING, BRAND INSTITUTE, PRODUCT NAME DEVELOPMENT SERVICES, GLOBAL BRANDING, BRANDING CONSULTANTS LOS ANGELES, NEW YORK, TORONTO, TOKYO, pharmaceutical product development.#Pharmaceutical #product #development

Posted On Jan 21 2018 by

Welcome to Brand Institute. We name more products than anyone in the world! Recent Healthcare Approvals Brand ing Brand Institute is the world’s premier brand identity consultancy. Our brand agency portfolio of services includes brand strategy/architecture, name development, market research, regulatory and visual identity solutions.


Pharmaceutical Drug Development Services, pharmaceutical product development.#Pharmaceutical #product #development

Posted On Jan 21 2018 by

pharmaceutical product development Experienced multi-disciplinary team providing flexible service options to deliver cost-effective and pragmatic development of pharmaceutical products to Phase 2b. S2PD supports clients in the following areas: Drug Development Planning Project Management S2PD has an experienced in-house drug development team to help clients with preclinical and early stage clinical phases. Our extensive experience in the space enables us to formulate plans and anticipate potential contingencies required. We know that work is often outsourced at short-notice with tight deliverable deadlines and sometimes with limited resources. S2PD will work with clients to define timelines, scope and resources required. Drug Candidate …


Product Liability Claims Involving Pharmaceutical Drugs, pharmaceutical product.#Pharmaceutical #product

Posted On Jan 10 2018 by

Product Liability Claims Involving Pharmaceutical Drugs If you have been injured by a pharmaceutical drug you used, you may have a defective products claim. Pharmaceutical-drug-based product liability claims are similar to other defective product claims, but pharmaceutical-related injury claims have a number of special features, which are discussed below. (To familiarize yourself with the basics of defective products claims in general, read Nolo’s article Product Liability FAQ.) Drug-related product liability claims come in three basic varieties: claims based on defectively manufactured pharmaceutical drugs; pharmaceutical drugs with dangerous side effects (even though properly manufactured); and improperly marketed pharmaceutical drugs. (These parallel …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharmacy #online

Posted On Dec 26 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …


Lupin Acquires Branded Product Portfolio from Shionogi in Japan #pharma #chemie

Posted On Dec 1 2017 by

#shionogi pharma # Lupin Acquires Branded Product Portfolio from Shionogi in Japan Mumbai, India and Osaka, Japan August 02, 2016: Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co. Ltd. (Head Office: Osaka, Japan; President Representative Director: Ray Tsunoda; hereafter “Kyowa”) has entered into a strategic asset purchase agreement with Shionogi Co. Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”), on August 1, 2016, to acquire 21 long-listed products from the Japanese pharma major, effective December 1, 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing …